REMARKS

Claims 42-47 are in this application. Claims 1-41 have been cancelled.

Claims 42-47 are being added. These correspond substantially to earlier presented claims:

New Claim	Earlier Presented Claim	
42	30	
43	31	
44	38	
45, 46, 47	41	

Applicants preserve all rights to file one or more divisional or continuation applications for subject matter disclosed in this application and not presently claimed.

In the Specification

Support for the amendment on page 27 to change "one-letter code" to "three-letter code" is based on the standard terminology used in the identification of amino acids. Also attached is a copy of Appendix 1 from the User's Manual for Patentln 3.3 which shows the correspondence between the one and three letter codes to identify amino acids.

The specification has been amended to replace "Closer description of the figures" with - -Brief Description of the Figures- -.

The Examiner's attention is drawn to the Amendment mailed to the USPTO on August 1, 2001 in which the second paragraph on page 8 was amended to refer to SEQ ID NO: 1 or 3 instead of SEQ ID NOs: 1 or 2.

The specification has been amended so that the SEQ ID Nos correspond to those of the Sequence Listing of March 10, 2003.

SEQ ID NO: 4 as filed on March 10, 2003 corresponds to the amino acid sequence shown in SEQ ID NO:2 in the originally filed application. The Sequence Listing filed January 29, 2002 contained an incorrect SEQ ID NO:4.

Claims

The objections to claim 30, 31 and 38 are moot in view of the new claims.

Support for the phrase in claims 42 and 43 "a biologically functional part thereof having uracil-DNA glycosylase activity" is found on page 7, lines 32-33 of the specification. Therefore, it is respectfully requested that the rejection under 35 USC 112, first paragraph be withdrawn.

Claims 30-38 and 41 were rejected under 35 USC 112, second paragraph.

The applicants note the examiner's comment that the enzyme is not able to be reactivated after being heated above about 60°C is inherent to the enzyme.

Claims 32-37 have been cancelled so the rejection under 35 USC 112 is moot. However, applicants preserve all to establish that the subject matter of claims 32-37 comply with the requirements of 35 USC 112, second paragraph.

The Examiner has rejected claim 41 under 35 USC 112, second paragraph on the bases that the use limitation does not limit the scope of the claim and the term "carry-over prevention" is unclear. This is respectfully traversed.

Firstly, since the enzymes of claims 42, 43 and 44 are novel and nonobvious a composition comprising the new and nonobvious enzyme is novel and nonobvious. Secondly, there is support for use of the enzyme in preventing experimental carry-over of active glycosylase in PCR reactions in the specification inter alia, at page 3, line 14-18; page 6, lines 24-27; page 8, lines 12-16 and example 4. It is respectfully requested this rejection be withdrawn.

Applicants submit that this application is in condition for allowance. If any issues remain it is respectfully requested that the Examiner contact the undersigned.

Respectfully submitted,

c/o Ladas & Parry LLP 26 West 61st Street New York, NY 10023

Reg. No. 33,778 (212) 708-1935



July 30, 2004 Version 2.4 Task Order Number CSC-04-04

User's Manual

for

PatentIn 3.3

Approved by:	Approved by:			
Program Manager	Date			

Prepared by:

Computer Sciences Corporation 2611 Jefferson Davis Highway, Suite 10,000 Arlington, VA 22202-4016



APPENDIX I ACCEPTABLE CHARACTERS IN THE SEQUENCE DESCRIPTION FIELD

Table I-1 provides an acceptable list of characters used as a filter for hand keying or importing DNA or RNA data into the sequence description field. PRT/1 and PRT/3 data lists are used during sequence listing project file generation when all single letter protein data is translated into amino abbreviated name (PRT/3) data.

Table -1: Acceptable Characters in the Sequence Description Field

DNA	RNA	DNA/RNA	Protein/1	Protein/3
a	. a	a	A	Ala
g	g	g	C *	Cys
c	С	С	D	Asp
t u	t '	E	Glu	
	u	F	Phe	
r	r	r	G	Gly
у	у	у	Н	His
m	m	m	I	Ile
k	k	k	K	Lys
S	S	S	L	Leu
w	w	w	M	Met
b	b	ь	N	Asn
d	d	d	P	Pro
h	h	h	Q	Gln
v	v	- v	R	Arg
n n	n	S	Ser	
		T	Thr	
		V	Val	
		W	Trp	
		Y	Tyr	
		В	Asx	
		Z	Glx	
		X	Xaa	